ImmunoGen, Inc. (NASDAQ:IMGN) – Stock analysts at Jefferies Group issued their Q2 2017 earnings per share estimates for shares of ImmunoGen in a report released on Tuesday. Jefferies Group analyst B. Amin anticipates that the biotechnology company will earn $0.17 per share for the quarter. Jefferies Group has a “Buy” rating and a $6.00 price objective on the stock. Jefferies Group also issued estimates for ImmunoGen’s FY2017 earnings at ($0.92) EPS.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings data on Friday, May 5th. The biotechnology company reported ($0.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.16. The firm had revenue of $28.70 million during the quarter, compared to the consensus estimate of $16.16 million. During the same quarter in the prior year, the business posted ($0.37) EPS. ImmunoGen’s revenue was up 45.7% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/07/21/immunogen-inc-to-post-q2-2017-earnings-of-0-17-per-share-jefferies-group-forecasts-nasdaqimgn.html.

Several other equities analysts also recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of ImmunoGen in a research report on Monday, June 26th. Leerink Swann raised ImmunoGen from a “market perform” rating to an “outperform” rating and upped their target price for the company from $3.53 to $3.90 in a research report on Wednesday, April 19th. ValuEngine raised ImmunoGen from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Royal Bank Of Canada raised ImmunoGen from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $5.00 to $12.00 in a research report on Thursday, July 6th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $5.00 target price on shares of ImmunoGen in a research report on Monday, May 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $6.76.

Shares of ImmunoGen (IMGN) opened at 5.90 on Friday. The firm has a 50 day moving average price of $5.94 and a 200-day moving average price of $4.05. ImmunoGen has a 12 month low of $1.51 and a 12 month high of $8.04. The company’s market cap is $527.15 million.

Large investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. boosted its stake in shares of ImmunoGen by 2.8% in the first quarter. Envestnet Asset Management Inc. now owns 27,761 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 743 shares during the period. Acadian Asset Management LLC bought a new stake in shares of ImmunoGen during the first quarter valued at about $117,000. Aperio Group LLC boosted its stake in shares of ImmunoGen by 45.1% in the second quarter. Aperio Group LLC now owns 16,797 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 5,221 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of ImmunoGen by 7.7% in the first quarter. Parametric Portfolio Associates LLC now owns 38,492 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 2,753 shares during the period. Finally, Stephens Inc. AR bought a new stake in shares of ImmunoGen during the first quarter valued at about $152,000. Institutional investors and hedge funds own 73.93% of the company’s stock.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Earnings History and Estimates for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.